For immediate release
Chicago, IL – February 8, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Amgen AMGN, TakeTwo Interactive TTWO, Chegg CHGG, Pfizer PFE and BP BP.
Here are the highlights from Monday’s analyst blog:
Mixed earnings for Amgen, TakeTwo; Chegg jump on the beat
All four major equity indices have now posted two negative trading days in the past three, with the Dow barely posting +0.004% gains today and avoiding a third straight lower trading day. The S&P 500 was flat half an hour before Monday’s closing bell, but fell -0.37% by the end. Similarly, the Nasdaq fell further into the red in the last half hour of trading, -0.58% on the day. The small cap Russell 2000 gained +0.51% in regular trading.
By sector, we see much the same picture we have had for some time: energy is again leading all industries, thanks to strong demand and higher prices; the laggards again were communications services and technology. Meanwhile, Treasury yields continue to climb over time: the 10yr is now at +1.914% and the 2yr at +1.294%. The Nasdaq is now -14% from its record highs of last November, while the S&P is -7% from its all-time highs reached in early January.
After Monday’s close, more companies announced their results, includingAmgen, which posted a mixed fourth quarter: earnings of $4.36 per share exceeded the Zacks consensus of $4.14, while revenue of $6.85 billion missed the $6.91 billion expected at the course of the quarter. This is the third consecutive earnings beat for the biotech major, and while sales of the osteoporosis drug Prolia rose +17% in the quarter, other treatments in the company’s portfolio underperformed. expectations. The shares were initially up late in the session, but are now exactly flat.
TakeTwo Interactive shares fell -5% before regaining some momentum in its third fiscal quarter, asGrand Theft Auto andNBA 2K The maker beat on earnings – $1.24 per share vs. $1.13 expected – but missed on sales: $866 million vs. $872 million in the Zacks consensus. The forecast for fourth quarter bookings disappointed, falling to 808-858 million against 924 million expected by analysts. TakeTwo has only had one shortfall in the past five years.
Silicon Valley-based education technology company Chegg is up a nice +15% after hours on its Monday afternoon Q4 beat and relaunch. Earnings of 38 cents per share on $207 million in sales beat the 31 cents per share and $195 million analysts were looking for. A 20% increase in services revenue helped the first-quarter revenue forecast to $200-205 million, versus $198 million in the Zacks consensus. Stocks are back to roughly where they were before a sharp drop in the share price in early November.
On Tuesday, we look forward to earnings reports from big companies like Pfizer and BP, as well as many others. On the economic reports side, look for an NHIB survey of small businesses for January and international trade figures for December, and actual household debt for the fourth quarter.
Questions or comments about this article and/or its author? Click here>>
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know our top 10 buy and hold tickers for all of 2022?
Last year 2021Zacks Top 10 Stocks the portfolio generated gains as high as +147.7%. Now, a brand new portfolio has been selected from over 4,000 companies covered by the Zacks ranking. Don’t miss your chance to participate in this long term shopping
Access the Top 10 Zacks Stocks for 2022 today >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
Zacks names ‘only one best choice for doubling up’
From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.
It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could jump in at any moment.
This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.
Free: See our best stock and our 4 finalists >>
Click to get this free report
BP plc (BP): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Inventory Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
TakeTwo Interactive Software, Inc. (TTWO): Free Stock Analysis Report
Chegg, Inc. (CHGG): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.